Gauri Varadhachary

2.9k total citations · 1 hit paper
25 papers, 2.1k citations indexed

About

Gauri Varadhachary is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gauri Varadhachary has authored 25 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gauri Varadhachary's work include Pancreatic and Hepatic Oncology Research (15 papers), Cancer Genomics and Diagnostics (8 papers) and Neuroendocrine Tumor Research Advances (5 papers). Gauri Varadhachary is often cited by papers focused on Pancreatic and Hepatic Oncology Research (15 papers), Cancer Genomics and Diagnostics (8 papers) and Neuroendocrine Tumor Research Advances (5 papers). Gauri Varadhachary collaborates with scholars based in United States, Brazil and Japan. Gauri Varadhachary's co-authors include Robert A. Wolff, Christopher H. Crane, Matthew H. G. Katz, James L. Abbruzzese, Peter W. T. Pisters, Jason B. Fleming, Jeffrey E. Lee, Huamin Wang, Michael J. Overman and Douglas B. Evans and has published in prestigious journals such as PLoS ONE, Cancer and Cancer Research.

In The Last Decade

Gauri Varadhachary

25 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018

2019 365 citations Jonathan M. Loree, Seerat Anand et al. JAMA Oncology profile →

Peers

Countries citing papers authored by Gauri Varadhachary

Since Specialization

Citations

This map shows the geographic impact of Gauri Varadhachary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gauri Varadhachary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gauri Varadhachary more than expected).

Fields of papers citing papers by Gauri Varadhachary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gauri Varadhachary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gauri Varadhachary. The network helps show where Gauri Varadhachary may publish in the future.

Co-authorship network of co-authors of Gauri Varadhachary

This figure shows the co-authorship network connecting the top 25 collaborators of Gauri Varadhachary. A scholar is included among the top collaborators of Gauri Varadhachary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gauri Varadhachary. Gauri Varadhachary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 breakdown → 2019 ·JAMA Oncology ·Jonathan M. Loree, Seerat Anand, Arvind Dasari, Joseph M. Unger, Anirudh Gothwal, Lee M. Ellis, Gauri Varadhachary, Scott Kopetz, Michael J. Overman, Kanwal Raghav	365
2	Medical oncology and pancreatic cancer: what the radiologist needs to know 2017 ·Abdominal Radiology ·David R. Fogelman, Gauri Varadhachary	1
3	Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes 2015 ·Annals of Oncology ·F Anthony San Lucas, Kelvin Allenson, Vincent Bernard, J. Castillo, (unknown), (unknown), Erik A. Ehli, Gareth E. Davies, Jason L. Petersen, (unknown), Robert A. Wolff, Matthew H. G. Katz, Gauri Varadhachary, Ignacio I. Wistuba, Anirban Maitra, Héctor M. Álvarez	155
4	Management of Borderline Resectable Pancreatic Cancer 2014 ·Seminars in Radiation Oncology ·Matthew H. G. Katz, Christopher H. Crane, Gauri Varadhachary	46
5	The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer 2013 ·Investigational New Drugs ·Mohamed A. Khalil, Wei Qiao, Peter J. Carlson, (unknown), Milind Javle, Michael J. Overman, Gauri Varadhachary, Robert A. Wolff, James L. Abbruzzese, David R. Fogelman	4
6	Radiographic Tumor–Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer 2013 ·Journal of Gastrointestinal Surgery ·Hop S. Tran Cao, (unknown), Huamin Wang, Christina E. Bailey, Jeffrey E. Lee, Peter W. T. Pisters, Douglas B. Evans, Gauri Varadhachary, Christopher H. Crane, Thomas A. Aloia, Jean‐Nicolas Vauthey, Jason B. Fleming, Matthew H. G. Katz, Graciela M. Nogueras‐González	85
7	Correction: Gene Expression Profiling of Ampullary Carcinomas Classifies Ampullary Carcinomas into Biliary-Like and Intestinal-Like Subtypes That Are Prognostic of Outcome 2013 ·PLoS ONE ·Michael J. Overman, Jiexin Zhang, Scott Kopetz, Michael A. Davies, Zhi-Qin Jiang, Katherine Stemke‐Hale, (unknown), Christian Pilarsky, (unknown), (unknown), Rosa F. Hwang, James L. Abbruzzese, Gauri Varadhachary, Bradley M. Broom, Huamin Wang	3
8	Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases 2012 ·European Radiology ·Priya Bhosale, (unknown), (unknown), Gauri Varadhachary, Valen E. Johnson, (unknown), Vikas Kundra	46
9	Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy 2012 ·HPB ·(unknown), Jason B. Fleming, Jeffrey E. Lee, Xuemei Wang, Peter W. T. Pisters, Jean‐Nicolas Vauthey, Gauri Varadhachary, Robert A. Wolff, Matthew H. G. Katz	69
10	Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators 2012 ·Cancer ·Matthew H. G. Katz, Jason B. Fleming, Priya Bhosale, Gauri Varadhachary, Jeffrey E. Lee, Robert A. Wolff, Huamin Wang, James L. Abbruzzese, Peter W. T. Pisters, Jean‐Nicolas Vauthey, Chusilp Charnsangavej, Eric P. Tamm, Christopher H. Crane, Aparna Balachandran	392
11	Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies 2010 ·BMC Cancer ·Milind Javle, Rachna T. Shroff, Henry Xiong, Gauri Varadhachary, David R. Fogelman, Shrikanth A.G. Reddy, Darren W. Davis, Yujian Zhang, Robert A. Wolff, James L. Abbruzzese	141
12	Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma 2009 ·Annals of Surgical Oncology ·Matthew H. G. Katz, Huamin Wang, Jason B. Fleming, Charlotte C. Sun, Rosa F. Hwang, Robert A. Wolff, Gauri Varadhachary, James L. Abbruzzese, Christopher H. Crane, Sunil Krishnan, Jean‐Nicolas Vauthey, Eddie K. Abdalla, Jeffrey E. Lee, Peter W. T. Pisters, Douglas B. Evans	381
13	The integration of chemoradiation in the care of patient with localized pancreatic cancer 2009 ·Cancer/Radiothérapie ·Christopher H. Crane, Gauri Varadhachary, Stephen H. Settle, Jason B. Fleming, Douglas B. Evans, Robert A. Wolff	14
14	Role of Adjuvant Chemoradiation Therapy in Adenocarcinomas of the Ampulla of Vater 2008 ·International Journal of Radiation OncologyBiologyPhysics ·Sunil Krishnan, Vishal Rana, Douglas B. Evans, Gauri Varadhachary, Prajnan Das, S. Bhatia, Marc E. Delclos, Nora A. Janjan, Robert A. Wolff, Christopher H. Crane, Peter W. T. Pisters	59
15	Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors 2008 ·Cancer Investigation ·Michael J. Overman, Scott Kopetz, Gauri Varadhachary, Masakazu Fukushima, (unknown), Akira Mita, Robert A. Wolff, Paulo M. Hoff, Henry Xiong, James L. Abbruzzese	53
16	Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors 2008 ·Investigational New Drugs ·Michael J. Overman, Gauri Varadhachary, Scott Kopetz, Melanie B. Thomas, Masakazu Fukushima, (unknown), Akira Mita, Robert A. Wolff, Paulo M. Hoff, Henry Xiong, James L. Abbruzzese	67
17	Patterns of Self-Reported Symptoms in Pancreatic Cancer Patients Receiving Chemoradiation 2007 ·Journal of Pain and Symptom Management ·Cielito C. Reyes‐Gibby, Wenyaw Chan, James L. Abbruzzese, Henry Q. Xiong, Linus Ho, Douglas B. Evans, Gauri Varadhachary, Samrat Bhat, Robert A. Wolff, Christopher H. Crane	46
18	The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer 2006 ·Best Practice & Research Clinical Gastroenterology ·Christopher H. Crane, Gauri Varadhachary, Robert A. Wolff, Peter W. T. Pisters, Douglas B. Evans	36
19	Preoperative and adjuvant therapies for upper gastrointestinal cancers 2005 ·Expert Review of Anticancer Therapy ·Gauri Varadhachary, Jaffer A. Ajani	8
20	Spontaneous pneumothorax in malignancy: A case report and review of the literature 2000 ·Annals of Oncology ·Shreya Srinivas, Gauri Varadhachary	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact